Our Innovative Vaccine Technology Platforms

iosBio’s competitive edge lies in our synergistic, patent-protected technology platforms. OraPro™ enables thermostable oral delivery, ESD™ optimizes immune responses, and our AI-driven approach designs superior antigens. Together, they form the foundation for our next-generation vaccines.

OraPro™ Oral Vaccine Platform

Enabling needle-free, cold chain-independent vaccination with enhanced mucosal immunity.

Learn more about OraPro™

Enhanced Surface Display (ESD™)

Maximising antigen presentation for rapid, robust, and durable immune responses.

Discover the ESD Advantage

AI-Assisted Antigen Design

Utilising computational power and biological insights to engineer best-in-class vaccine antigens.

Explore our AI-Driven Approach

Follow us

Keep up to date with our news and find out more about investment opportunities with iosBio.

The team of doctors and scientists at iosBio believe that the next great leap forward in immunization will be oral delivery

Enabling the fastest and most cost-effective deployment of vaccines the world has ever seen. This is not just a huge leap forward from a humanitarian perspective, oral vaccine technology also represents a significant commercial opportunity.

Contact us on

info@iosbio.com / 01444 241911

or fill out the form below.





    We will not, in any circumstances share your personal information with other individuals or organizations without your permission.